AUROBINDO PHARMA LTD. - 524804 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find attached certificate under Reg.74(5) of SEBI (DP) Regulations 2018.11-10-2023
11-10-2023
AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We bring to your kind notice that the Company has received the letters from shareholders informing about the loss of share certificates and requested for issue of duplicate share certificates.04-10-2023
AUROBINDO PHARMA LTD. - 524804 - Reply To Clarification Sought On Increase In The Volume Of Shares Traded On The Stock Exchanges.
With reference to your e-mail ref. No. L/SURV/ONL/PV/KS/2023-2024/ 343 dated 03.10.2023, we are submitting the clarification sought on increase in the volume of shares traded on the stock exchanges.03-10-2023
AUROBINDO PHARMA LTD. - 524804 - Clarification sought from Aurobindo Pharma Ltd
The Exchange has sought clarification from Aurobindo Pharma Ltd on October 3, 2023, with reference to Movement in Volume.The reply is awaited.03-10-2023
Aurobindo Pharma falls 2.5% after US FDA observation on Telangana unit
We will respond to the USFDA within the stipulated timelines and work closely with USFDA to close the observation at the earliest, company said.03-10-2023
AUROBINDO PHARMA LTD. - 524804 - Completion Of Sale And Transfer Of API Units To Apitoria Pharma Private Limited, A Wholly Owned Subsidiary
Update on completion of sale and transfer of API Non-antibiotic Business and API Antibiotics Business to Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company.01-10-2023
AUROBINDO PHARMA LTD. - 524804 - Completion Of US FDA Inspection At Our Unit VI - B
The US FDA inspected the Company''s Unit VI-B, a formulation facility from September 22 to September 29, 2023 and at the end of the inspection a Form 483 was issued with one observation which is procedural in nature.30-09-2023
AUROBINDO PHARMA LTD. - 524804 - Closure of Trading Window
Closure of trading window for the financial results for the second quarter ending on 30th September 2023.27-09-2023
AUROBINDO PHARMA LTD. - 524804 - Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Auro Vaccines Private Limited, a wholly owned subsidiary of the Company, has entered into a Licence Agreement with Hilleman Laboratories Singapore Pte. Ltd., to develop, manufacture and commercialise a pentavalent vaccine candidate used in children vaccination.27-09-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform that the officials of the Company will be participating in the f investor / analyst meeting on September 26, 2023.21-09-2023